Curran W J, Kornstein M J, Brooks J J, Turrisi A T
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111.
J Clin Oncol. 1988 Nov;6(11):1722-7. doi: 10.1200/JCO.1988.6.11.1722.
To evaluate the role of mediastinal irradiation (RT) following surgery for invasive thymomas, a clinical and pathologic review of 117 patients with the diagnosis of thymoma was completed. Fourteen cases were excluded because of the lack of histologic criteria for a thymic tumor, and the remaining 103 were classified according to a staging system as follows: stage I, completely encapsulated (43); stage II, extension through the capsule or pericapsular fat invasion (21); stage III, invasion of adjacent structures (36); and stage IV, thoracic dissemination or metastases (3). The 5-year actuarial survival and relapse-free survival rates were 67% and 100% for stage I, 86% and 58% for stage II, and 69% and 53% for stage III. No recurrences occurred among stage I patients after total resection without RT. However, eight of 21 patients with invasive (stage II or III) thymomas had mediastinal recurrence as the first site of failure following total resection without RT. The 5-year actuarial mediastinal relapse rate of 53% in this group compares unfavorably with the mediastinal relapse rate seen among stage II or III cases following total resection with RT (0%) or following subtotal resection/biopsy with RT (21%). Despite attempted salvage therapy, five of eight patients with mediastinal relapse following total resection alone died of progressive disease. No significant difference was observed in the local relapse rate, overall relapse rate, or survival between those patients undergoing biopsy and RT v subtotal resection and RT for invasive thymomas (stages II and III). Total resection alone appears to be inadequate therapy resulting in an unacceptably high local failure rate with poor salvage therapy results.
为评估侵袭性胸腺瘤手术后纵隔放疗(RT)的作用,我们对117例诊断为胸腺瘤的患者进行了临床和病理回顾。14例因缺乏胸腺肿瘤的组织学标准而被排除,其余103例根据分期系统分类如下:I期,完全包膜完整(43例);II期,肿瘤穿透包膜或侵犯包膜周围脂肪(21例);III期,侵犯相邻结构(36例);IV期,胸腔播散或转移(3例)。I期患者的5年精算生存率和无复发生存率分别为67%和100%,II期为86%和58%,III期为69%和53%。I期患者在未接受放疗的情况下进行全切除后未出现复发。然而,21例侵袭性(II期或III期)胸腺瘤患者中有8例在未接受放疗的情况下进行全切除后,纵隔复发是首次失败部位。该组5年精算纵隔复发率为53%,与II期或III期病例在接受全切除加放疗(0%)或次全切除/活检加放疗(21%)后的纵隔复发率相比不利。尽管尝试了挽救治疗,但仅接受全切除后纵隔复发的8例患者中有5例死于疾病进展。对于侵袭性胸腺瘤(II期和III期)患者,接受活检加放疗与次全切除加放疗的局部复发率、总复发率或生存率之间未观察到显著差异。单纯全切除似乎是一种不充分的治疗方法,导致局部失败率高得令人无法接受,挽救治疗效果不佳。